Tags : ReveraGen

Idorsia Transfers its Agreement with ReveraGen to Santhera for Vamorolone

Shots: Idorsia transfers its development & commercialization agreement with ReveraGen to Santhera, whereby Santhera shall replace Idorsia as a party to the agreement.  Santhera to get an exclusive license, including sublicensing rights, for vamorolone in all indications globally, including Japan and South Korea and a share in expected PR voucher In exchange for the revised […]Read More